New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma

Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained in patients following completion of treatment with Polivy plus BR, compared to 17.5% (n=7/40) with BR alone, indicating responses to the Polivy regimen were durable. No new or delayed safety signals were reported. Furthermore, n ew data from an extension cohort showed a CR rate of 38.7% (n=41/106) with Polivy plus BR. These results, which were presented as a poster (Abstract #3020) at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on 5-8 December 2020, further support the clinical be nefit this Polivy-based combination brings to patients with this aggressive disease.“Despite recent advances, treatment options are needed that can improve survival outcomes, enhance convenience, and support a good quality of life for patients with relapsed or refractory diffuse large B-cell lymphoma,” said Levi Garraway, M.D....
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsIn this study, we showed TEW-7197 and ramucirumab considerably decreased invasiveness, thus EMTness in a panel of diffuse-type GC cell lines including GC PDCs. Taken together, we confirmed that combination of TEW-7197 and ramucirumab reduced tumor spheroid and GC PDC-induced blood vessel formation concomitantly in the spheroid-on-a-chip model.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
AbstractBehavioral traits like aggression, anxiety, and trainability differ significantly across dog breeds and are highly heritable. However, the neural bases of these differences are unknown. Here we analyzed structural MRI scans of 62 dogs in relation to breed-average scores for the 14 major dimensions in the Canine Behavioral Assessment and Research Questionnaire, a well-validated measure of canine temperament. Several behavior categories showed significant relationships with morphologically covarying gray matter networks and regional volume changes. Networks involved in social processing and the flight-or-fight respon...
Source: Anatomy and Embryology - Category: Anatomy Source Type: research
The objective of the study was to explore the effect of the PARK16 rs11240572 variant on brain structure in PD patients. A total of 51 PD patients were enrolled in the study and genotyped for the rs11240572 variant. Clinical assessments and MRI scans were conducted across all participants. Voxel-based morphometry (VBM) was used to investigate gray matter volume (GMV) of the whole brain between these two groups. Correlation analysis was performed to identify the relationships between GMV and clinical features. There were 17 rs11240572-A variant carriers and 34 non-carriers, with no significant demographic differences betwee...
Source: Anatomy and Embryology - Category: Anatomy Source Type: research
In conclusion, the study showed that the novel RDI metric is sensitive to density of small and large axons in adults and children, with both single- and multi-shell acquis ition DWI data. Its effectiveness and availability to be used on standard as well as advanced DWI acquisitions makes it a promising method in clinical settings.
Source: Anatomy and Embryology - Category: Anatomy Source Type: research
Systematically mapping the mechanical properties of skin and tissue is useful for biomechanics research and disease diagnostics. For example, later stage breast cancer and lymphoma manifest themselves as hard nodes under the skin. Currently, mechanical measurements are done manually, with a sense of touch or a handheld tool. Manual measurements do not provide quantitative information and vary depending on the skill of the practitioner. Research shows that tactile sensors could be more sensitive than a hand. We propose a method that uses our previously developed skin-crawling robots to noninvasively test the mechanical prop...
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Conclusion: The proposed model is shown to adequately describe the meal-induced glucose fluctuations in simulated CGM data while validations on clinical CGM data show promising results as well. Significance: The proposed model may lay the grounds for new ways of utilizing available CGM data, including CGM-based parameter estimation and stochastic optimal control.
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
This study shows that the LVADs can respond appropriately to changing patient states and physiological demands without the need for additional pressure or flow measurements.
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Biotechnology | Cancer | Cancer & Oncology | Diabetes | Endocrinology | Food and Drug Administration (FDA) | France Health | Genetics | Hematology | Hodgkin's Disease | Infectious Diseases | International Medicine & Public Health | Internet | Japan Health | Leukemia | Lymphoma | Marketing | Men | Molecular Biology | Non-Hodgkin's Lymphoma | Opthalmology | PET Scan | Pharmaceuticals | Primary CNS Lymphoma | Rituxan | Science | Stem Cell Therapy | Stem Cells | Study | Switzerland Health | Transplants | Treanda | USA Health | WHO